Australia Vaccine Market Size & Outlook, 2026-2033
- Pharmaceuticals
- Vaccines
- Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the vaccine market
Australia vaccine market highlights
- The Australia vaccine market generated a revenue of USD 2,166.9 million in 2025 and is expected to reach USD 3,716.8 million by 2033.
- The Australia market is expected to grow at a CAGR of 6.8% from 2026 to 2033.
- In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
- Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2025 | USD 2,166.9 million |
| Market revenue in 2033 | USD 3,716.8 million |
| Growth rate | 6.8% (CAGR from 2026 to 2033) |
| Largest segment | Viral vaccines |
| Fastest growing segment | Other Indication |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 3.0% of the global vaccine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China vaccine market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,198.2 million by 2033.
The favorable regulatory framework and high demand for influenza vaccines in the country are likely to boost market growth. For instance, in March 2022, Seqirus announced that its Flucelvax Quad (quadrivalent influenza vaccine) was approved by the Therapeutic Goods Administration (TGA) for children aged 2 years and older.
This was the first one-cell-based flu vaccine in the country. Furthermore, positive trial results of vaccine candidates are likely to provide momentum to the country’s market growth. For instance, in April 2022, Novavax published clinical data for the combined flu and COVID-19 vaccine, with promising outcomes. This trial was conducted in Australia.
Vaccination is strongly recommended for people at highest risk; for instance, children under 2 years, people aged 15 to 19, and international travelers. Earlier, the meningococcal ACWY vaccine was funded by NIP for infants aged 12 months and above. In 2019, it was funded for 10-year-olds through a school program. Moreover, increasing introduction of novel meningococcal vaccines in the country will drive market growth.
No credit card required*
Publish Date: Jul 28, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
Australia Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 65.42% in 2025.
Horizon Databook has segmented the Australia vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
The favorable regulatory framework and high demand for influenza vaccines in the country are likely to boost market growth. For instance, in March 2022, Seqirus announced that its Flucelvax Quad (quadrivalent influenza vaccine) was approved by the Therapeutic Goods Administration (TGA) for children aged 2 years and older.
This was the first one-cell-based flu vaccine in the country. Furthermore, positive trial results of vaccine candidates are likely to provide momentum to the country’s market growth. For instance, in April 2022, Novavax published clinical data for the combined flu and COVID-19 vaccine, with promising outcomes. This trial was conducted in Australia.
Vaccination is strongly recommended for people at highest risk; for instance, children under 2 years, people aged 15 to 19, and international travelers. Earlier, the meningococcal ACWY vaccine was funded by NIP for infants aged 12 months and above. In 2019, it was funded for 10-year-olds through a school program. Moreover, increasing introduction of novel meningococcal vaccines in the country will drive market growth.
- Australia Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Viral Vaccines
- Bacterial Vaccines
- Cancer Vaccines
- Allergy Vaccines
- Other Indication
- Australia Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
- Subunit Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- Australia Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Nasal
- Australia Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Pediatric Age Group
- Adult Age Group
- Australia Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
- Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Vaccine Market, 2021-2033 (US$M)
Australia vaccine market statistics, by indication, 2021-2033 (US$M)
